BSA
GILD icon

Braun Stacey Associates’s Gilead Sciences GILD Stock Holding History

Braun Stacey Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Buy
+102,562
New +$13.5M 0.37% 81
2016
Q4 		– Sell
-6,055
Closed -$479K – 157
2016
Q3 		$479K Sell
6,055
-42,592
-88% -$3.46M 0.03% 128
2016
Q2 		$4.06M Sell
48,647
-6,680
-12% -$593K 0.26% 104
2016
Q1 		$5.08M Buy
55,327
+4,170
+8% +$376K 0.33% 98
2015
Q4 		$5.18M Buy
51,157
+44,380
+655% +$4.62M 0.33% 96
2015
Q3 		$665K Sell
6,777
-3,893
-36% -$432K 0.04% 114
2015
Q2 		$1.25M Buy
10,670
+6,805
+176% +$744K 0.05% 183
2015
Q1 		$379K Sell
3,865
-8,170
-68% -$830K 0.02% 129
2014
Q4 		$1.13M Buy
12,035
+6,110
+103% +$632K 0.07% 111
2014
Q3 		$631K Buy
5,925
+3,075
+108% +$301K 0.04% 117
2014
Q2 		$236K Buy
+2,850
New +$222K 0.01% 151

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braun Stacey Associates's GILD Position: Q2 2026 in Review

Braun Stacey Associates opened a new position in Gilead Sciences (GILD) in Q2 2026: 102,562 shares worth $13M. The stake represents 0.37% of the portfolio and ranks #81 among its holdings. This is a return to the name: Braun Stacey Associates previously reported a position in GILD as recently as Q3 2016.

Braun Stacey Associates first reported a position in GILD in Q2 2014 and has held it in 11 quarters since. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Braun Stacey Associates held 102,562 shares of Gilead Sciences worth $13M as of Q2 2026.
  • Gilead Sciences was a new Braun Stacey Associates position in Q2 2026.
  • Gilead Sciences made up 0.37% of Braun Stacey Associates's portfolio in Q2 2026, its #81 holding.
  • Braun Stacey Associates first reported a position in Gilead Sciences in Q2 2014 and has held it in 11 quarters since.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Braun Stacey Associates's 13F filing for Q2 2026, filed 5 Aug 2026.